A carregar...
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anti-cancer drug development. Wild-type BRAF and a variety of oncogenic BRAF mutants are dependent on dimerization of the kinase domain, w...
Na minha lista:
| Publicado no: | ACS Chem Biol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6733264/ https://ncbi.nlm.nih.gov/pubmed/31243962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00191 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|